Deutsche Bank AG Invests $3.07 Million in Relay Therapeutics, Inc. $RLAY

Deutsche Bank AG acquired a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 164,036 shares of the company’s stock, valued at approximately $3,069,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Commodore Capital LP acquired a new stake in Relay Therapeutics in the 2nd quarter valued at approximately $46,191,000. Perceptive Advisors LLC boosted its position in shares of Relay Therapeutics by 412.3% during the first quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company’s stock worth $97,024,000 after buying an additional 7,847,896 shares during the period. Spruce Street Capital LP purchased a new position in shares of Relay Therapeutics during the fourth quarter worth $25,246,000. EcoR1 Capital LLC acquired a new stake in shares of Relay Therapeutics in the first quarter valued at $18,952,000. Finally, TCG Crossover Management LLC acquired a new stake in shares of Relay Therapeutics in the third quarter valued at $9,450,000. Institutional investors and hedge funds own 96.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on RLAY. Citigroup reissued a “market outperform” rating on shares of Relay Therapeutics in a research note on Monday, August 10th. Barclays lifted their target price on Relay Therapeutics from $27.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. JonesTrading raised shares of Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. JPMorgan Chase & Co. raised their price objective on shares of Relay Therapeutics from $28.00 to $31.00 and gave the company an “overweight” rating in a research note on Friday, August 14th. Finally, Citizens Jmp lifted their price objective on shares of Relay Therapeutics from $21.00 to $26.00 and gave the company a “market outperform” rating in a report on Monday, August 10th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $25.92.

Insider Buying and Selling

In related news, CFO Thomas Catinazzo sold 187,163 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $16.97, for a total transaction of $3,176,156.11. Following the sale, the chief financial officer directly owned 177,461 shares in the company, valued at approximately $3,011,513.17. This represents a 51.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Donald A. Bergstrom sold 93,456 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $16.94, for a total transaction of $1,583,144.64. Following the completion of the sale, the insider directly owned 418,557 shares in the company, valued at approximately $7,090,355.58. This trade represents a 18.25% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 409,639 shares of company stock valued at $7,233,399. Corporate insiders own 5.04% of the company’s stock.

Relay Therapeutics Trading Down 5.4%

Shares of NASDAQ RLAY opened at $19.46 on Thursday. The stock has a market cap of $4.26 billion, a P/E ratio of -12.39 and a beta of 1.69. The business’s fifty day simple moving average is $19.14 and its 200-day simple moving average is $14.64. Relay Therapeutics, Inc. has a 12-month low of $3.49 and a 12-month high of $21.27.

Relay Therapeutics (NASDAQ:RLAY) last released its earnings results on Thursday, August 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The company had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.96 million. On average, equities analysts forecast that Relay Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Relay Therapeutics Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.